Sarepta Therapeutics, Inc. (SRPT) was founded in 1980 and is based in Cambridge, Massachusetts. The company is focused on developing RNA-based therapeutics and gene therapy against Duchenne muscular ...
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two ...
- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback